Millennium Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Millennium Management’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-357,411	Closed	-$194K	–	4069
2016 Q3	$194K	Sell	357,411 -102,917	-22%	-$47.1K	﹤0.01%	2993
2016 Q2	$268K	Buy	+460,328	New	+$491K	﹤0.01%	2786
2016 Q1	–	Sell	-24,391	Closed	-$78K	–	4035
2015 Q4	$78K	Sell	24,391 -1,909	-7%	-$9.18K	﹤0.01%	3273
2015 Q3	$164K	Buy	26,300 +13,176	+100%	+$123K	﹤0.01%	3175
2015 Q2	$130K	Buy	+13,124	New	+$115K	﹤0.01%	3128
2014 Q2	–	Sell	-17,418	Closed	-$126K	–	4315
2014 Q1	$126K	Buy	+17,418	New	+$103K	﹤0.01%	3274

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

CDH

Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

MBT

Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Millennium Management's NWBO Position: Q4 2016 in Review

Millennium Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 357,411 shares — an estimated $194K sold.

Millennium Management first reported a position in NWBO in Q1 2014 and held it in 6 quarters. The position peaked at $268K in Q2 2016. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

Millennium Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
Millennium Management sold 357,411 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $194K.
Millennium Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2014 and held it in 6 quarters.
Millennium Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $268K in Q2 2016.
8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Millennium Management's 13F filing for Q4 2016, filed 14 Feb 2017.